Disease · HP_0002039
Anorexia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Anorexia. Diseases, record HP_0002039. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002039
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Anorexia
- Open Targets ID
- HP_0002039
- Other names
- Deliberately not eating, Obsessive dieting, Refusing to eat
- Highest stage of its drugs
- Approval, for 4 of its 15 drugs, from DailyMed
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MEGESTROL ACETATE | CHEMBL1201139 | Small molecule | Approval | DailyMed | 12 | 9 | 9 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Approval | DailyMed | 2 | 1 | 0 | Drugs and targets |
| DIVALPROEX SODIUM | CHEMBL2105613 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| METOCLOPRAMIDE HYDROCHLORIDE | CHEMBL1200940 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ANAMORELIN | CHEMBL2110579 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ETANERCEPT | CHEMBL1201572 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ICOSAPENT | CHEMBL460026 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NABIXIMOLS | CHEMBL3833333 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets18
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | 3 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Approval | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GHSR | Growth hormone secretagogue receptor type 1 | 2 | Ghrelin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2693 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 2 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Approval | https://conductscience.org/library/genes/7915 | Drugs and targets |
| CCDC6 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | 1 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | Early phase 1 | https://conductscience.org/library/genes/8030 | Drugs and targets |
1 to 10 of 18
See all 18 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1 | Phase 3 | 318 | 2024-06-26 | Cachexia; Cancer, Non Small Cell Lung Cancer | ANAMORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | Phase 1 | 18 | 2024-01-12 | Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia | PONSEGROMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00637728 | Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients | Phase 3 | 5 | 2016-02-29 | Anorexia, Cachexia, Weight Loss | MEGESTROL ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00637806 | Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension | Phase 3 | 4 | 2016-05-02 | Anorexia, Cachexia, Weight Loss | MEGESTROL ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | Phase 2 | 4 | 2025-11-17 | Metastatic Pancreatic Cancer | ANAMORELIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01200602 | Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy | Phase 2 | 1 | 2013-05-24 | Anorexia, Weight Changes | MEGESTROL ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00031707 | Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite | Phase 3 | 429 | Anorexia, Cachexia | ICOSAPENT, MEGESTROL ACETATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04939090 | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | 227 | Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm | MEGESTROL ACETATE, OLANZAPINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02619266 | The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers | Phase 2/3 | 160 | Anorexia, Cancer Cachexia | MEGESTROL ACETATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00488072 | Effects of Mirtazapine on Appetite in Advanced Cancer Patients | Phase 2 | 98 | Advanced Cancer, Anorexia, Weight Loss, Insomnia | MIRTAZAPINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 100 mg Anamorelin HCl vs Placebo: deaths from any cause | 27 of 159 | 26 of 159 | 318 | NCT03743051 | Trial comparisons |
| 100 mg Anamorelin HCl vs Placebo: serious adverse events | 43 of 159 | 39 of 159 | 318 | NCT03743051 | Trial comparisons |
| Anamorelin vs Placebo: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0 | 0 of 2 | 1 of 2 | 4 | NCT04844970 | Trial comparisons |
| Anamorelin vs Placebo: deaths from any cause | 0 of 2 | 1 of 2 | 4 | NCT04844970 | Trial comparisons |
| Anamorelin vs Placebo: serious adverse events | 0 of 2 | 1 of 2 | 4 | NCT04844970 | Trial comparisons |
Papers from its trials29
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002039
GET https://conductscience.org/api/diseases/v1/HP_0002039/papers?page=2